AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23298394
Drug: Radiofrequency-induced heat
RxNorm normalized name: heather pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency-induced heat therapy (RFHT) for 30-60 seconds
Trial: 23298394
Drug: Intralesional sodium
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intralesional sodium stibogluconate (SSG) injections (50 mg cm(‐2) of lesion, seven injections)
Trial: 20659937
Drug: Nystatin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nystatin (1 ml suspension, 100,000 U/ml, every 8 h)
Trial: 20659937
Drug: Fluconazole (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (3 mg/kg body weight, every third day)
Trial: 19074465
Drug: LB03002 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB03002 at 0.2 mg/kg
Trial: 19074465
Drug: LB03002 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB03002 at 0.5 mg/kg
Trial: 19074465
Drug: LB03002 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB03002 at 0.7 mg/kg
Trial: 19074465
Drug: LB03002 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB03002 at all doses
Trial: 17685721
Drug: Tapering (TAP)
RxNorm normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tapering (TAP) for 4 weeks
Trial: 15050497
Drug: No rescue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No rescue treatment (Control)
Trial: 11720096
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg MDMA (first dose)
Trial: 11720096
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg MDMA (second dose, 4 hours after first)
Trial: 11720096
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg MDMA (second dose, 24 hours after first)
Trial: 11720096
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg MDMA (two doses, 4 hours apart)
Trial: 11720096
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg MDMA (two doses, 24 hours apart)
Trial: 9340923
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (estrogen replacement therapy)
Trial: 3479456
Drug: Adjunctive irrigation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive irrigation with chlorhexidine or hydrogen peroxide
Trial: 18270832
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (2.5 mg and higher)
Trial: 15523305
Drug: unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: unfractionated heparin or enoxaparin + IIb/IIIa inhibition
Trial: 15523305
Drug: IIb/IIIa inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIb/IIIa inhibitors (upstream drug initiation)
Trial: 15523305
Drug: IIb/IIIa inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIb/IIIa inhibitors (during angioplasty only)
Trial: 8374115
Drug: Contrast-enhanced MR
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced MR imaging (CE-MRI) with intravenous application of a contrast agent (0.1 mmol Gd-DTPA/kg)
Trial: 17802784
Drug: 4 courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 courses of 7+3+VP‐16 and 5 courses of maintenance therapy (7+3 with thioguanin)
Trial: 17802784
Drug: 2 courses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 courses of 7+3+VP‐16, 2 HAD courses, treatment discontinuation
Trial: 11816441
Drug: Quinine sulphate
RxNorm normalized name: Quinine sulphate
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine sulphate for 3 days followed by single-dose sulfadoxine-pyrimethamine (Q3 + SP, Group II)
Trial: 11816441
Drug: Mefloquine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine 20 mg/kg single dose (MEF, Group IV)
Trial: 952756
Drug: Salicylic acid
RxNorm normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salicylic acid in aqueous cream or white soft paraffin at concentrations of 2-12% applied to normal skin.
Trial: 25078385
Drug: Intravenous lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lignocaine (1.5mg/kg bolus at intubation followed by 1.5mg/kg/h infusion until 1h post-surgery)
Trial: 9040543
Drug: Energy-dense milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Energy-dense milk cereal formula (5 kJ/g, 11% protein)
Trial: 9040543
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (milk-cereal formula with 2.5 kJ/g, 11% protein)
Trial: 30590877
Drug: 1.2-g LCPUFA-ω3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2-g LCPUFA-ω3 daily for 3 months
Trial: 30590877
Drug: 1-g sunflower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-g sunflower oil daily for 3 months (Control)
Trial: 20801942
Drug: Systematic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic treatment programme (experimental group)
Trial: 20801942
Drug: Routine occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine occupational therapy (control group)
Trial: 17375319
Drug: Early onset
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early onset cognitive behavioural therapy
Trial: 17375319
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no early onset cognitive behavioural therapy)
Trial: 25386453
Drug: Ivermectin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (200 μg/kg body weight) oral in a single dose
Trial: 25386453
Drug: Topical Permethrin
RxNorm normalized name: permethrin Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Permethrin 5% cream single application
Trial: 25386453
Drug: Topical gamma
RxNorm normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gamma benzene hexachloride (GBHC) lotion 1% single application
Trial: 25386453
Drug: Topical Benzyl
RxNorm normalized name: benzyl alcohol Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Benzyl benzoate (BB) lotion 25% single application
Trial: 23033919
Drug: Supplement (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement (120 mg of N-oleyl-phosphatidyl-ethanolamine and 105 mg of epigallocatechin-3-gallate)
Trial: 15105028
Drug: Supplement
RxNorm normalized name: fat supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement
Trial: 17324047
Drug: 30-mg cortisol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-mg cortisol
Trial: 9568442
Drug: Eradication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eradication therapy for H. pylori
Trial: 8092559
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone propionate 100 micrograms twice daily
Trial: 8092559
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone propionate (200 micrograms once daily or 100 micrograms twice daily)
Trial: 2964468
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (no-treatment group)
Trial: 27457469
Drug: Latanoprostene bunod
RxNorm normalized name: Latanoprostene bunod
DrugBank: Latanoprostene bunod (DB11660)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Latanoprostene bunod (LBN) ophthalmic solution 0.024%
Trial: 25885543
Drug: Qishe pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qishe pill (3.75 grams)
Trial: 25885543
Drug: Qishe pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qishe pill (7.5 grams)
Trial: 25885543
Drug: Qishe pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qishe pill (15 grams)
Trial: 15181134
Drug: Thyroglobulin (Tg)
RxNorm normalized name: thyroglobulin
DrugBank: Thyroglobulin (DB01584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroglobulin (Tg) levels measured just before (131)I ablative therapy (Tg1)
Trial: 9323144
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy and continuous-course radiotherapy (Arm B)
Trial: 8457239
Drug: Nimesulide (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (200 mg suppository, t.i.d. for 2 days)
Trial: 8457239
Drug: Paracetamol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (500 mg suppository, t.i.d. for 2 days)
Trial: 20405515
Drug: Methylprednisolone monotherapy
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone monotherapy (MpMT) (32 mg/m2/day IV x 3 days)
Trial: 15781794
Drug: Mechanical bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical bowel preparation (MBP) with Soffodex
Trial: 15781794
Drug: Non-mechanical bowel
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-mechanical bowel preparation (non-MBP)
Trial: 10943959
Drug: Glucose‐ORS (G‐ORS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose‐ORS (G‐ORS)
Trial: 1583307
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 (200 mg orally, 48 hours before Sulprostone injection)
Trial: 1583307
Drug: RU 486
RxNorm normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU 486 treatment
Trial: 23348641
Drug: Deep sedation
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep sedation (G1) with propofol (1mg/kg) and continuous infusion of propofol (25‐50mg/kg/min) and remifentanil (0.01‐0.05 mg / kg / min)
Trial: 23348641
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (G2) with propofol (2mg/kg) and continuous infusion of propofol (60‐100mg/kg/min) and remifentanil (0.06 to 0.1g/kg/min)
Trial: 20486868
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) for 6 months in women without RAAS blockade
Trial: 20486868
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) for 6 months in women with RAAS blockade
Trial: 19064745
Drug: ethyl‐EPA, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ethyl‐EPA, 1 g twice a day
Trial: 15955148
Drug: Incentive spirometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incentive spirometry (IS) for 2 months with medical treatment
Trial: 9562208
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus Mianserin
Trial: 9562208
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus Placebo
Trial: 8572086
Drug: Ineraid cochlear
RxNorm normalized name: Cochlearia officinalis leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ineraid cochlear implant
Trial: 21991809
Drug: rhGMCSF gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGMCSF gel
Trial: 21991809
Drug: gel matrix
RxNorm normalized name: Sil_k Pad Gel Matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gel matrix (control group)
Trial: 17270384
Drug: Risk factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk factor tested (which may be a drug) in case-control studies
Trial: 16200777
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of rhTPO at doses of 0.25, 0.5, 1.0, and 2.0 microg/kg
Trial: 16200777
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of rhTPO at 1.0 microg/kg for 7 - 14 days
Trial: 26291137
Drug: FF/VI 200/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/VI 200/25 mcg
Trial: 7838417
Drug: beta‐IFN therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐IFN therapy at a dose of 300,000 UI/die i.m. for 7 days, continuing the same dose on alternate days for 2 weeks
Trial: 3283097
Drug: Enoxacin 400
RxNorm normalized name: enoxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin 400 mg single dose
Trial: 23906646
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (OT) administered to the parent
Trial: 19664250
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment of malaria in infants (IPTi) delivered through the expanded programme of immunization (EPI)
Trial: 19664250
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose infant formulations of IPTi
Trial: 19664250
Drug: Newer drugs
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer drugs used in IPTi
Trial: 17045409
Drug: Citalopram IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram IV infusion (20 mg over 120 min)
Trial: 1577936
Drug: Slow release
RxNorm normalized name: Slow Release Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow release intrauterine insemination (treatment A)
Trial: 1577936
Drug: Bolus intrauterine
RxNorm normalized name: UREA 13 g INTRAUTERINE TABLET [INTRAUTERINE BOLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus intrauterine insemination (treatment B)
Trial: 30997650
Drug: Optimal Sampling
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal Sampling Strategy (OSS) using time points of 2, 4, and 8 hours post-dose for first-line anti-TB drugs (isoniazid, rifampicin, ethambutol, pyrazinamide)
Trial: 26891645
Drug: Pilates sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilates sessions in addition to conventional treatment with occlusal splint
Trial: 26891645
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with occlusal splint
Trial: 22437411
Drug: Higher hemoglobin
RxNorm normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher hemoglobin (13-15 g/dl)
Trial: 22437411
Drug: Lower hemoglobin
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower hemoglobin (9-11 g/dl)
Trial: 18271233
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) warming therapy combined with oral administration of Pyridostigmine (90 ‐ 240 mg each day) and Prednisone (30 ‐ 60 mg each day)
Trial: 18271233
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Pyridostigmine (240‐480 mg each day) and Prednisone (60‐100 mg each day)
Trial: 16279900
Drug: PEG IFN
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG IFN alpha‐2b 1.5 microg/kg per wk plus RBV 800 mg per day (Regimen A)
Trial: 16279900
Drug: PEG IFN
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG IFN alpha‐2b 1.0 microg/kg per wk plus RBV 1,000‐1,200 mg per day (Regimen B)
Trial: 16279900
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy nonresponders
Trial: 16279900
Drug: IFN monotherapy
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN monotherapy nonresponders
Trial: 16279900
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy relapsers
Trial: 16279900
Drug: HCV ribonucleic
RxNorm normalized name: ribonucleic acid sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV ribonucleic acid levels <100,000 copies/mL
Trial: 11872551
Drug: Homoeopathic immunotherapy
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homoeopathic immunotherapy
Trial: 10195529
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL of bupivacaine 0.25%
Trial: 10195529
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of bupivacaine 0.5%
Trial: 10195529
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of saline
Trial: 9626172
Drug: L-arginine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (3 g TID for 6 months)
Trial: 6126441
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg diacetolol
Trial: 6126441
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg diacetolol
Trial: 6126441
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg diacetolol
Trial: 30233159
Drug: Resveratrol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol (500 mg/day) with meloxicam (Mlx)
Trial: 26818756
Drug: Muscle vibration
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscle vibration treatment at 200 Hz
Trial: 26818756
Drug: Muscle vibration
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscle vibration treatment at 100 Hz
Trial: 24818764
Drug: Low-dosage EPA-E
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dosage EPA-E (1800 mg/d)
Trial: 24818764
Drug: High-dosage EPA-E
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage EPA-E (2700 mg/d)
Trial: 22639399
Drug: Supervised exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised exercise program (1 hour twice a week)
Trial: 18613959
Drug: 1-year group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-year group behavioral program based on Self-Determination Theory (SDT) with 30 sessions of 2 hours each, delivered weekly or bi-weekly.
Trial: 11818200
Drug: CEF14 (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF14 (chemotherapy every 14 days)
Trial: 11818200
Drug: CEF21 (chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF21 (chemotherapy every 21 days)
Trial: 9880419
Drug: Collagen-gentamicin implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagen-gentamicin implant plus metronidazole 20 to 40 mg/kg/day IV for 7 days
Trial: 9880419
Drug: Open wounds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open wounds treated with local cleansing, metronidazole 20 to 40 mg/kg/day IV and gentamicin 5 mg/kg/day IV for 7 days
Trial: 2024227
Drug: Ampicillin, gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin, gentamicin and clindamycin (standard therapy)
Trial: 28934785
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive sacroiliac joint fusion (SIJF) using triangular titanium implants
Trial: 17507306
Drug: Enfuvirtide plus
RxNorm normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enfuvirtide plus one of the new ritonavir‐boosted protease inhibitors (tipranavir or darunavir) and an optimised background treatment regimen
Trial: 10068730
Drug: Triple regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple regimen PAC (pantoprazole 40 mg bid, clarithromycin 500 mg tid, amoxicillin 1 g bid)
Trial: 2178870
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tenoxicam daily
Trial: 2178870
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg diclofenac twice daily
Trial: 88710
Drug: Hydromorphone (narcotic)
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone (narcotic) delivered in a demand analgesia (DA) system, dosage varied in response to patient-triggered apparatus.